Recombinant IGF-1/BP3 protects against intestinal injury in a neonatal mouse NEC model

期刊论文
发表日期：

2024年2月28日

查看全文

Xiaocai Yan,
Elizabeth Managlia,
Galen Carey,
Norman Barton,
Xiao-Di Tan,
Isabelle G. De Plaen

摘要

Background

Recombinant human IGF-1/binding protein-3 (rhIGF-1/BP3) is currently being tested in phase II clinical trials in premature infants to prevent bronchopulmonary dysplasia, but its impact on the neonatal intestine remains unclear. The aim of this study was to determine whether rhIGF-1/BP3 protects against necrotizing enterocolitis (NEC) in mice and to investigate the mechanisms involved.

Methods

Neonatal mice were dam fed or injected intraperitoneally with rhIGF-1/BP3 (or vehicle) and submitted to an experimental NEC model. Serum IGF-1 was assessed by ELISA and intestinal vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expression by Western blot. Intestinal endothelial cell proliferation, and enterocyte proliferation and migration were examined by immunofluorescence. Pup survival and histological intestinal injury were determined.

Results

In pups exposed to experimental NEC, serum IBP3-bound IGF-1 level was decreased. Exogenous rhIGF-1/BP3 preserved VEGF and VEGFR2 protein expression, decreased vascular permeability, and preserved endothelial cell proliferation in the small intestine. Furthermore, rhIGF-1/BP3 promoted enterocyte proliferation and migration, which effects were attenuated by inhibiting VEGFR2 signaling, decreased enterocyte apoptosis and decreased systemic and intestinal inflammation. rhIGF-1/BP3 improved survival and reduced the incidence of severe intestinal injury in experimental NEC.

Conclusions

Exogenous rhIGF-1/BP3 protects neonatal mice against experimental NEC via multiple mechanisms.

Impact

Exogenous rhIGF-1/BP3 preserves intestinal microvascular development and integrity, promotes enterocyte proliferation and migration, decreases local and systemic inflammation, and protects neonatal mice against NEC.

The article adds pre-clinical evidence of a protective role for rhIGF-1/BP3 on the premature gut.

It provides evidence supporting the use of rhIGF1/BP3 in premature neonates to protect against NEC.